Why Kazia Therapeutics Limited’s (KZIA) Stock Is Down 6.47%
As of Friday, July 10, Kazia Therapeutics Limited’s KZIA share price has dipped by 6.47%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Commentary & Analysis
Why Kazia Therapeutics Limited’s (KZIA) Stock Is Up 8.01%
As of Monday, June 08, Kazia Therapeutics Limited’s KZIA share price has surged by 8.01%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Kazia Therapeutics Limited’s (KZIA) Stock Is Up 10.19%
As of Monday, June 08, Kazia Therapeutics Limited’s KZIA share price has surged by 10.19%, which has investors questioning if this is right time to sell.Tudor Pop
Why Kazia Therapeutics Limited’s (KZIA) Stock Is Up 5.66%
As of Thursday, June 04, Kazia Therapeutics Limited’s KZIA share price has surged by 5.66%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Kazia Therapeutics Limited’s (KZIA) Stock Is Down 7.47%
As of Tuesday, May 26, Kazia Therapeutics Limited’s KZIA share price has dipped by 7.47%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | KZIA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $120.7 | $237.5 | 24% |
|
| Shares Out (Mil) | 2.1 | 53.9 | 8% |
|
| Institutional Ownership | 67.2% | 93.1% | 42% |
|
| Float (Mil) | 11.4 | 41.4 | 21% |
|
| Beta | 2.18 | 0.95 | 94% |
|
| Avg Daily Volume (000s) | 157 | 628 | 41% |
|
| Price Change (52-week) |
22.7% | 49.0% | 71% |
|
| Growth | KZIA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 11.4% | 12.4% | 63% |
|
| Net Income (5yr) | (9.6%) | (10.2%) | 30% |
|
| EPS (5yr) | 26.8% | 15.7% | 78 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (36.0%) | (15.7%) | 14% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | KZIA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 2% |
|
| Net Income (TTM) (Mil) | ($15) | ($44) | 26% |
|
| EPS (TTM) | ($6.817) | ($1.600) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($10) | ($33) | 20% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $90 | $174 | 20% |
|
| Valuation | KZIA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.23 | 2.27 | 69% |
|
| P/E | na | 19.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | KZIA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (52.0%) | (47.7%) | 11% |
|
| ROE | (106.2%) | (55.0%) | 9% |
|
| Liabilities to Assets | 34.7% | 29.4% | 26% |
|
| F-Score | 4 | 2 | 33% |
|
Kazia Therapeutics Limited did not pass any screens on 10/12/2026.
